Scientific Advisors

Michael Jay, Ph.D. - Co-Founder of NanoMed Pharmaceuticals, Inc., is a professor of pharmaceutical sciences at the University of Kentucky College of Pharmacy and has a joint appointment in the Department of Diagnostic Radiology of the UK Chandler Medical Center. Dr. Jay is a member of the Pharmaceutics, Drug Delivery and Analysis area of graduate study (AGS) and has ongoing collaborations with faculty within and outside of the College. He also served as the Director of the Center for Pharmaceutical Science and Technology (CPST) from 1998-2007 and the Executive Director of Economic Development and Innovations Management from 2003-2007.

David D. Allen, R.Ph., Ph.D., is the founding dean of pharmacy and professor of pharmaceutical sciences at the Northeastern Ohio Universities College of Pharmacy and professor of physiology and pharmacology in the Northeastern Ohio Universities College of Medicine. He received his bachelor's degree in pharmacy at the University of Kentucky and then worked in community pharmacy for several years before returning to the University of Kentucky to earn his doctorate in pharmaceutical sciences. In addition, Allen served as an intramural research training award postdoctoral fellow at NIH in Bethesda, Maryland. He has had grant support for his research from international, national, state and local funding sources, including the NIH, the American Heart Association, the American Association of Colleges of Pharmacy, the Chilean government and industrial sources. Allen has published 60 peer-reviewed articles, 30 professional publications, 70 abstracts and presented his work over 130 times across the United States and Abroad.

J. Patrick McGovren, Ph.D., is a longtime and well-known cancer research specialist, holding senior positions in big pharma oncology departments, as well as extensive consulting experience. He was involved in the discovery and/or development of nine clinically evaluated anti-tumor drugs and has significant clinical trial operations and IND/NDA submission experience. Currently, Dr. McGovren is VP, Preclinical Development of ProNai Therapeutics, Inc., an emerging biopharmaceutical company that is leveraging its novel and proprietary nucleic acid-based interfering technology, DNAi®, to advance a next generation of therapies for patients with cancer and other complex genetic diseases. Prior to joining ProNAi, Dr. McGovren was most recently Research Director, Clinical Pharmacology, Medical Development at Pfizer, following a term as Clinical Research Manager,Oncology Medical Affairs at Pharmacia. Between 1976 and 2000, Dr. McGovren held numerous senior research and management posts at    Pharmacia & Upjohn.

Charles Bibart, Ph.D., Dr. Bibart has over 25 years experience in new drug development, technology transfer and manufacturing. Most recently, he held the position of Group Vice President - Active Pharmaceutical Ingredients for Pharmacia. Responsibilities included executive management of all chemical and biopharmaceutical bulk active ingredient plants, as well as, pilot development facilities and all process development functions. Prior experiences included executive management of preclinical development functions including analytical development, pharmaceutical development, drug metabolism, and drug safety at The Upjohn Company. Over the years, he has been involved in the development of over a hundred drug and product candidates working on the discovery-development interface and the development-manufacturing interface. Dr. Bibart received his bachelor's degree in chemistry from Hope College and his Ph.D. degree in Physical Chemistry from Indiana University.

Susan R. Mallery, D.D.S., Ph.D., Professor, College of Dentistry, Oral Maxillofacial Surgery & Pathology, The Ohio State University. Dr. Mallery’s research interests include regulation of cell cycle progression; in-teraction of cellular thiol redux status with mitogen responsiveness; association of cellular calcium status with cellular proliferation and differentiation in endothelial cells; and regulation of angiogenesis and neo-vascularization.  Dr. Mallery and Dr. Mumper are co-inventors and collaborated on the development of the BioAdhesive Berry Gel for which NanoMed has an Option to an exclusive license; a phase I/Ia clinical study commenced December 15, 2005.